Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1993 1
1994 1
1995 2
1996 1
1997 1
1999 1
2003 3
2007 1
2008 3
2009 2
2010 1
2011 1
2012 2
2013 3
2014 1
2015 2
2016 5
2017 2
2018 2
2019 5
2020 4
2021 7
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Results by year

Filters applied: . Clear all
Page 1
Telmisartan, ramipril, or both in patients at high risk for vascular events.
ONTARGET Investigators; Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. ONTARGET Investigators, et al. N Engl J Med. 2008 Apr 10;358(15):1547-59. doi: 10.1056/NEJMoa0801317. Epub 2008 Mar 31. N Engl J Med. 2008. PMID: 18378520 Free article. Clinical Trial.
Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
Pieber TR, Bode B, Mertens A, Cho YM, Christiansen E, Hertz CL, Wallenstein SOR, Buse JB; PIONEER 7 investigators. Pieber TR, et al. Lancet Diabetes Endocrinol. 2019 Jul;7(7):528-539. doi: 10.1016/S2213-8587(19)30194-9. Epub 2019 Jun 9. Lancet Diabetes Endocrinol. 2019. PMID: 31189520 Clinical Trial.
Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.
Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators; Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, et al. Lancet. 2008 Sep 27;372(9644):1174-83. doi: 10.1016/S0140-6736(08)61242-8. Epub 2008 Aug 29. Lancet. 2008. PMID: 18757085 Clinical Trial.
Capecitabine-induced hypertriglyceridemia and hyperglycemia: two cases.
Duman BB, Paydas S, Tetiker T, Gunaldı M, Afsar CU, Erçolak V, Haksöyler V, Dilli MŞ. Duman BB, et al. Among authors: tetiker t. Pharmacology. 2012;90(3-4):212-5. doi: 10.1159/000342382. Epub 2012 Sep 13. Pharmacology. 2012. PMID: 23038659 Review.
HbA1c level decreases in iron deficiency anemia.
Çetinkaya Altuntaş S, Evran M, Gürkan E, Sert M, Tetiker T. Çetinkaya Altuntaş S, et al. Among authors: tetiker t. Wien Klin Wochenschr. 2021 Feb;133(3-4):102-106. doi: 10.1007/s00508-020-01661-6. Epub 2020 May 6. Wien Klin Wochenschr. 2021. PMID: 32377869
Hypogonadotropic Hypogonadism due to Novel FGFR1 Mutations.
Akkuş G, Kotan LD, Durmaz E, Mengen E, Turan İ, Ulubay A, Gürbüz F, Yüksel B, Tetiker T, Topaloğlu AK. Akkuş G, et al. Among authors: tetiker t. J Clin Res Pediatr Endocrinol. 2017 Jun 1;9(2):95-100. doi: 10.4274/jcrpe.3908. Epub 2016 Dec 23. J Clin Res Pediatr Endocrinol. 2017. PMID: 28008864 Free PMC article.
48 results